Frédéric Triebel

11.2k citations

167 papers · 9.2k indexed · 2 hit papers · h-index 54

Immunology top 0.1%
- Immunotherapy and Immune Responses 79
- Immune Cell Function and Interaction 73
- T-cell and B-cell Immunology 58
- Immune Response and Inflammation 8
Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers 76
- CAR-T cell therapy research 38
Virology top 5%
Genetics top 5%
Radiology, Nuclear Medicine and Imaging top 2%
- Monoclonal and Polyclonal Antibodies Research 26
Pulmonary and Respiratory Medicine
- Ferroptosis and cancer prognosis 7

Co-authors: Thierry Hercend S Jitsukawa Bertrand Huard Florence Faure Sergio Roman‐Roman Catherine Genevée Elena Baixerás Chrystelle Brignone
Cited by: Immunology Oncology Virology
Journals: The Journal of Immunology (19 papers)European Journal of Immunology (18 papers)Journal of Clinical Oncology (13 papers)
Partner nations: France United States United Kingdom

In The Last Decade

Frédéric Triebel

166 papers receiving 8.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Frédéric Triebel

Since Specialization

Citations

This map shows the geographic impact of Frédéric Triebel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Triebel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Triebel more than expected).

Fields of papers citing papers by Frédéric Triebel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Triebel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Triebel. The network helps show where Frédéric Triebel may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Frédéric Triebel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frédéric Triebel Line = papers co-authored together Frédéric Triebel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study Margarita Majem,Enric Carcereny,Bernard Doger,Timothy Clay,Igor Bondarenko,Julio A. Peguero,Manuel Cobo,Martin Förster,Ewa Kalinka‐Warzocha,Bayu Prayogi,Laia Vilà,Wade T. Iams,Matthew Krebs,Begoña Campos,Christian Mueller,(unknown),Frédéric Triebel	2025	0
2	Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma Clinical Cancer Research ·Martin Förster,Irene Braña,Antonio López–Pousa,Bernard Doger,Patricia Roxburgh,Hande Karamahmutoğlu,Julio A. Peguero,Matthew Krebs,Enric Carcereny,Jialing Li,Syed Ali Aamir Imam,Chrystelle Brignone,Frédéric Triebel	2024	8
3	AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization. Journal of Clinical Oncology ·Frédéric Forget,Serafín Morales,Nuhad K. Ibrahim,燕荣,Omkar Marathe,Jean-Luc Canon,Pavani Chalasani,Konstantinos Papadimitriou,Mafalda Oliveira,Elia Seguí,Frédéric Triebel	2024	1
4	Crystal structure of the human LAG-3–HLA-DR1–peptide complex Science Immunology ·Jan Petersen,A. J. Cuerda,浜田絵里奈,KORYAUSHKINA A A.V.,Frédéric Triebel,Jamie Rossjohn	2024	4
5	LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1 Annals of Oncology ·Qiannan Yu,Robert L. Metcalf,Addyson E Sand,Simon Laban,Tiara Ardiani,G Bähr,(unknown),Mineia da Costa Figueiredo,Sebastian M. Dieter,(unknown),Stefan Kasper‐Virchow,Orro Stammer y Otros,Voin Bojinov,Florian D. Vogl,Hélène IABUSSIÈRE,Frédéric Triebel	2024	1
6	Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial Clinical Cancer Research ·Hans Wildiers,Anne Armstrong,Eveline Cuypere,Florence Dalenc,Luc Dirix,Markets,Frederik Marmé,Carolina P. Schröder,Jens Huober,François P. Duhoux,Peter Vuylsteke,Agnes Jager,Étienne Brain,Yudha Andriansyah Putra,Zsuzsanna Pápai,C. Willemien Menke‐van der Houven van Oordt,C.P. Rimini,Syed Ali Aamir Imam,Chrystelle Brignone,Frédéric Triebel	2023	12
7	1266P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma Annals of Oncology ·Margarita Majem,Enriqueta Felip,Bernard Doger,比呂美久保,Enric Carcereny,Timothy Clay,Matthew Krebs,Julio A. Peguero,Frédéric Triebel	2020	4
8	Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial Clinical Cancer Research ·Amandine Legat,Hélène Maby–El Hajjami,Petra Baumgaertner,Laurène Cagnon,Samia Abed Maillard,Christine Geldhof,Emanuela M. Iancu,Luc Lebon,Philippe Guillaume,Danijel Dojcinovic,Olivier Michielin,Emanuela Romano,Grégoire Berthod,Donata Rimoldi,Frédéric Triebel,Immanuel F. Luescher,Nathalie Rufer,Daniel E. Speiser	2015	76
9	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancerbreakdown → Clinical Cancer Research ·Nicolás A. Giraldo,Étienne Becht,Franck Pagès,Georgios Skliris,Virginie Verkarre,Yann Vano,Arnaud Méjean,Nicolas Saint-Aubert,Laetitia Lacroix,Ivo Natario,Audrey Lupo,Marco Alifano,Diane Damotte,Aurélie Cazes,Frédéric Triebel,Gordon J. Freeman,Marie‐Caroline Dieu‐Nosjean,Stéphane Oudard,Wolf H. Fridman,Catherine Sautès‐Fridman	2015	356
10	LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites The Journal of Immunology ·Chiara Camisaschi,Chiara Casati,Francesca Rini,Michela Perego,Annamaria De Filippo,Frédéric Triebel,Giorgio Parmiani,Filiberto Belli,Licia Rivoltini,Chiara Castelli	2010	271
11	A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma Clinical Cancer Research ·Chrystelle Brignone,Bernard Escudier,Caroline Grygar,Manon Marcu,Frédéric Triebel	2009	178
12	Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation The Journal of Immunology ·Chiara Casati,Chiara Camisaschi,Luisa Novellino,Arabella Mazzocchi,Frédéric Triebel,Licia Rivoltini,Giorgio Parmiani,Chiara Castelli	2008	15
13	Identification of a human CD8 ⁺ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4 Proceedings of the National Academy of Sciences ·Simone A. Joosten,Krista E. van Meijgaarden,Nigel D. L. Savage,Tjitske de Boer,Frédéric Triebel,Annemieke van der Wal,Emile de Heer,Michèl R. Klein,Annemieke Geluk,Tom H. M. Ottenhoff	2007	157
14	A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells The Journal of Immunology ·Chrystelle Brignone,Caroline Grygar,Manon Marcu,Knut Schäkel,Frédéric Triebel	2007	60
15	Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy Drug Discovery Today ·Jagadeesh Bayry,Sophie Sibéril,Frédéric Triebel,David F. Tough,Srini V. Kaveri	2007	56
16	Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity Cancer Research ·Chiara Casati,Chiara Camisaschi,Francesca Rini,Flavio Arienti,Licia Rivoltini,Frédéric Triebel,Giorgio Parmiani,Chiara Castelli	2006	60
17	Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223) The Journal of Immunology ·Susanne Andreae,Mitsue Kikuchi,Nicolas Burdin,Frédéric Triebel	2002	155
18	A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens The Journal of Immunology ·N Sawamura,Frédéric Triebel	2000	55
19	The T-cell receptor Vδ genes predominantly used by human peripheral γ/δ+ T lymphocytes are not rearranged in CD3− natural killer cells Human Immunology ·Sergio Roman‐Roman,Elena Baixerás,Catherine Genevée,Thierry Hercend,Frédéric Triebel	1989	1
20	CD3/Ti gamma A: a functional gamma -receptor complex expressed on human peripheral lymphocytes. The Journal of Immunology ·Florence Faure,S Jitsukawa,Frédéric Triebel,Thierry Hercend	1988	35

About Frédéric Triebel

Frédéric Triebel is a scholar working on Immunology, Oncology, Radiology, Nuclear Medicine and Imaging, Biotechnology and Hematology, having authored 167 papers that have together received 9.2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (79 papers), Cancer Immunotherapy and Biomarkers (76 papers), Immune Cell Function and Interaction (73 papers), T-cell and B-cell Immunology (58 papers), CAR-T cell therapy research (38 papers), Monoclonal and Polyclonal Antibodies Research (26 papers), Immune Response and Inflammation (8 papers) and Ferroptosis and cancer prognosis (7 papers). The work is most often cited by research in Immunology (7.0k citations), Oncology (5.2k citations), Virology (199 citations), Genetics (320 citations) and Radiology, Nuclear Medicine and Imaging (679 citations). Frédéric Triebel has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Thierry Hercend, S Jitsukawa, Bertrand Huard, Florence Faure, Sergio Roman‐Roman, Catherine Genevée, Elena Baixerás, Chrystelle Brignone, Sigrid Hannier and Philippe Prigent. Their work appears in journals such as The Journal of Immunology, European Journal of Immunology, Journal of Clinical Oncology, International Journal of Cancer and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact